Austerity threatens pharma beyond borders of cost cutters

With austerity measures tightening across Europe, and governments looking for quick cost-saving wins, drug prices have found themselves on the chopping board across the continent. But while politicians rejoice at having figured out how to stretch shrinking healthcare budgets, the pharmaceutical sector wonders where it will end.

If you cut revenue streams, then clearly that's something the manufacturers need to absorb elsewhere," says Colin Mackay, a spokesman for the European Federation of Pharmaceutical Industries and Associations, a Belgium-based pharmaceutical lobby group. He points to employment and drug research and development programs as probable victims.

In Greece, where financial instability has been particularly severe, the government implemented sweeping average drug price cuts of 21.5% in May. These emergency reductions are due to expire in August. Nevertheless, Danish diabetes giant Novo Nordisk, along with some smaller companies, subsequently withdrew products over fears of operating at a loss. Novo Nordisk eventually struck a deal with the government in mid-June to start resupplying its insulins, but not before incurring the opprobrium of patient groups.

Yet although the Greek drama has captured the headlines, other governments have been leading the charge for cheaper drugs.

Spain slashed 25% off generics in March and

Paying the price: Drugmakers hit by lower prices.

simultaneously revised its pricing scheme to drive down the price of branded drugs. In May, the country forced firms to sacrifice a further 7.5% of their revenue for patent-protected meds. All told, these cuts will cost the pharma sector, or save Spain, €1.3 billion (\$1.6 billion).

Germany also started making moves in March to chop up to 16% off what it pays for drugs and to overhaul its pricing system.

Other countries, including Italy, France and Ireland, are also considering, or have already introduced, cuts of one form or another. Because many European countries set prices for their drugs by taking into account the average costs in several other countries, returns might fall even in markets that don't take cost-saving measures.

"It's unsustainable for the pharmaceutical industry to take any more hits," cautions Julián Zabala, a spokesman for the industry association Farmaindustria in Madrid.

Another hurdle

For Christopher McCabe, a health economist at the University of Leeds, UK, prices may have a chance to rebound once budgets start to rise again. That is, he says, if companies can overcome the emerging hurdle of value-based pricing (VBP), in which drug prices directly reflect health benefits.

The UK's new coalition government wants to introduce VBP by 2014. And the National Institute for Health and Clinical Excellence (NICE) — which decides which drugs are affordable for the UK's National Health Service—is already experimenting with the paradigm. Comparative effectiveness studies are being used to assess whether multiple sclerosis drugs are priced appropriately, for instance, and reimbursements for nonresponders are being used to improve the cost effectiveness of cancer therapies.

"Some versions of these are undoubtedly price discounts in disguise," says McCabe. As such schemes evolve and continue to catch on across Europe, he says, companies will have to avoid the riskier clinical trials, as their high costs inflate the prices of drugs that do make it to market.

The sooner pharma factors VBP into research and development decisions, adds McCabe, "the quicker it will find it can continue to make very healthy profits."

Asher Mullard, London

Pharma fesses up to freebies

Pharmaceutical companies have long handed out free drug samples as a way to promote their products directly to physicians. Although watchdogs have estimated that the total retail price of freebies exceeds \$18 billion per year (*N. Engl. J. Med.* **357**, 673–681, 2007), the industry has traditionally kept such information a closely guarded secret. Thanks to the new US healthcare bill, however, starting in 2012 pharma firms will be compelled to disclose their giveaways.

"Samples are a very important marketing tool," says Allan Coukell, director of the Pew Prescription Project. "This [disclosure] will allow policymakers to get a better picture of what's clearly one driver of prescribing practices and of costs."

Ahead of the law change, several US-based companies voluntarily reported their donations from 2007 to Congress. Some companies counted samples by dose, whereas others counted by unit; prices are based on either market price or wholesale cost.

	Samples	Value (\$ million)
Pfizer	101 million	2,700
Merck	39 million	356
Eli Lilly	33 million	67
Wyeth (now part of Pfizer)	52 million	64
Abbott	16 million	32
Baxter	33,000	7

Source: Dow Jones

Correction

In the print version of the June 2010 issue of *Nature Medicine*, the byline was missing for the article entitled 'In vision trial, some researchers would rather see double' (*Nat. Med.* **16**, 611, 2010). The author was Elie Dolgin. The error did not appear in the HTML and PDF versions of the article.